Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2023
-
- participants needed
- 575
-
- sponsor
- National Taiwan University Hospital
Summary
The primary aim of this open-label, randomized control trial is to compare the immunogenicity at week 28 after 20g HBV vaccine (at week 0, 4, 24) versus 40g HBV vaccine (40-g at week 0, 4, 24 week) among HIV-positive patients or HIV-negative MSM who were born in Taiwan after July 1986 and tested negative for all HBV serological markers. The secondary aims are to assess the safety of double-dose HBV vaccination, the proportions of high-level responders (anti-HBs antibody >100 mIU/ml) at weeks 28 and 48, the serological responses at week 48, and incident HBV infection (indicated by appearance of anti-HBc and/or HBsAg) at week 48.
Description
I. Study procedures:
- Well explain, complete inform and consent documents
- A blood test for hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antibody (anti-HBs antibody), anti-hepatitis B core antibody (anti-HBc antibody), anti-HCV and RPR will be performed first.
- The patients with all negative seromarkers (within 1 month) will be allocated to two groups (random blank=4), a standard-dose booster of 20g and a double-dose booster of 40g. For patients receiving 40g, two 20g of vaccines are injected at both sides of deltoid muscles. The schedules of booster vaccination are the same in two groups, which is at 0, 1, 6 months.
- To detect and manage possible immediate and severe allergic reaction, patients who received vaccination will be observed for 30 minutes after injection.
- The solicited adverse effect will be recorded on the diary card if occurred in 7 days after each dose of vaccination.
- The titer of hepatitis B surface antibody will be examined before booster vaccination, at the 4th week, the 24th week, 28th week, 48th week. By comparing the responses in the two groups, the effect of different doses of booster vaccination can be evaluated. For those HIV-negative individuals at baseline, HIV screening test will be evaluated every 6 months during the study, at the 24th week, the 48th.
- To screen the acquisition of hepatitis B, the anti-HBc antibody and HBsAg will be examined at the 48th week
- To screen the acquisition of hepatitis C and syphilis, anti-HCV and RPR will be examined at the 24th week, the 48th week
- The results of the study will be informed by phone or the physician during the follow-up care.
- The serum/blood samples will be preserved in the research lab of the department of internal medicine and kept for 20 years. During this period, the sample will be applied or used in other studies after the patients and the Research Ethics Committee both agreed.
- During the follow-up care, the treatment or record of hospitalization will be recorded or reviewed.
- The participants will drop out of clinical trial when protocol violation occurred or the participant is not willing to continue.
Details
| Condition | HIV infection, HIV Infections, Immunodeficiency, Primary Immunodeficiency Disorders, Hepatitis B, Hepatitis B, Primary Immunodeficiency Disorders, HIV Infections, Immunization; Infection, Immunization; Infection, human immunodeficiency virus, hiv disease, Immunization; Infection |
|---|---|
| Treatment | Engerix-B |
| Clinical Study Identifier | NCT03854630 |
| Sponsor | National Taiwan University Hospital |
| Last Modified on | 24 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer